Becton, Dickinson and Company

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +35

Becton Dickinson stock edges lower as conference highlights Alaris headwind and dividend payout

AI-generated analysis

πŸ“‰ Becton, Dickinson and Company shares closed down 3.0% at $179.10 on September 8, 2026, trading within its 52-week range of $127.62 to $193.07.

πŸ“ˆ The company reported 4.4% organic revenue growth in fiscal Q3 2026, marking the first full quarter operating as a focused entity post-divestitures.

πŸ”„ Management raised full-year guidance for fiscal 2026 to the upper end of the low-single-digit range, projecting sustained momentum from recent performance.

⚠️ Fiscal 2027 outlook is cautious with low-single-digit growth expectations due to a mechanical headwind of roughly 200 basis points from Alaris infusion system comparisons.

🌏 Pricing pressures in China contributed approximately 250 basis points of headwinds to fiscal 2026 revenue, offset by positive pricing elsewhere in the global portfolio.

πŸ’° The company utilized around $2 billion from the Waters transaction proceeds for share repurchases in fiscal 2026 to return capital to shareholders.

πŸ’΅ BDX declared a quarterly dividend of $1.05 per share with an ex-dividend date of September 9, 2026, annualizing to a yield of about 2.3%.

🎯 Analyst consensus maintains a Hold rating with an average target price of $187.67, placing the current stock price roughly 4.8% below the mean target.

πŸ“Š GuruFocus data indicates BDX shares trade approximately 2.6% below its proprietary GF Value estimate of $183.88 as of September 8, 2026.

Bullish Signals
  • Becton, Dickinson and Company achieved 4.4% organic revenue growth in fiscal Q3 2026, demonstrating strong momentum across roughly 90% of its portfolio following strategic divestitures.
  • Management raised full-year guidance for fiscal 2026 to the upper end of the low-single-digit range, signaling confidence that recent performance can be sustained throughout the year.
  • The company successfully absorbed over $130 million in negative price impact from China's value-based procurement programs while maintaining positive pricing across the rest of its fiscal 2026 operations.
  • BD utilized approximately $2 billion in proceeds from the Waters transaction for share repurchases in fiscal 2026, reinforcing its commitment to capital returns alongside growth investments.
  • The company declared a quarterly dividend of $1.05 per share with an ex-dividend date of September 9, 2026, providing income-focused investors with a yield of about 2.3%.
Risk Factors
  • Combined pressures from the Alaris system, vaccines, and China pricing created approximately 250 basis points of headwinds to fiscal 2026 revenue growth.
  • The company faces ongoing pricing pressure in China due to value-based procurement programs, which negatively impacted reported revenue despite offsetting gains elsewhere.
Full Analysis
Becton, Dickinson and Company (BDX) shares edged lower on September 8, 2026, trading at $179.10 after management highlighted a strategic shift toward a slimmer portfolio following the spin-off of Embecta and the separation of its life sciences business to Waters. At the Wells Fargo Healthcare Conference, executives emphasized that fiscal third quarter 2026 marked the first full period of operation as a more focused entity, delivering 4.4% organic revenue growth with roughly 90% of the portfolio achieving high-single-digit expansion. Looking ahead, the company raised its full-year guidance for fiscal 2026 to the upper end of the low-single-digit range, signaling confidence that recent momentum can be sustained. However, management issued a cautious outlook for fiscal 2027, projecting only low-single-digit revenue growth due to mechanical headwinds from the Alaris infusion system comparison and pricing pressures in China. The company quantified these specific headwinds at approximately 250 basis points for fiscal 2026 and roughly 200 basis points for fiscal 2027. Capital allocation remains a key pillar of BD's strategy, with management noting that around $2 billion in proceeds from the Waters transaction have been utilized for share repurchases in fiscal 2026. Additionally, the company declared a quarterly dividend of $1.05 per share with an ex-dividend date of September 9, 2026, offering a yield of approximately 2.3% at current prices. Analyst consensus currently rates BDX as a Hold with an average target price of $187.67, suggesting the stock trades slightly below fair value estimates.